Cargando…

Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions

The increasing number of approved therapies for relapsed mantle cell lymphoma (MCL) provides patients effective treatment options, with increasing complexity in prioritization and sequencing of these therapies. Chemo-immunotherapy remains widely used as frontline MCL treatment with multiple targeted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bond, David A, Martin, Peter, Maddocks, Kami J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000187/ https://www.ncbi.nlm.nih.gov/pubmed/33799484 http://dx.doi.org/10.3390/jcm10061207

Ejemplares similares

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Mantle Cell Lymphoma Relapsing at the Lymphedematous Arm
por: Massini, Giuseppina, et al.
Publicado: (2013)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
por: Sawalha, Yazeed, et al.
Publicado: (2020)

Current overview and treatment of mantle cell lymphoma
por: Schieber, Michael, et al.
Publicado: (2018)

Relapsed Mantle Cell Lymphoma Presenting as “Sister Mary Joseph Nodule”
por: Vaughn, Jennifer E., et al.
Publicado: (2010)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

Current trials for frontline therapy of mantle cell lymphoma
por: Steiner, Raphael E., et al.
Publicado: (2018)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
por: Bock, A., et al.
Publicado: (2022)

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
por: Epperla, Narendranath, et al.
Publicado: (2022)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma
por: Linton, Kim, et al.
Publicado: (2020)

Progress in molecular feature of smoldering mantle cell lymphoma
por: Jiang, Panruo, et al.
Publicado: (2021)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

Management of mantle cell lymphoma in the elderly patient
por: Doorduijn, Jeanette K, et al.
Publicado: (2013)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
por: Russler-Germain, David A., et al.
Publicado: (2023)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022)

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
por: Wang, Michael, et al.
Publicado: (2017)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Treatment Outcomes and Survival Patterns of Asian Patients With Relapsed/Refractory Mantle Cell Lymphoma
por: Tan, Jing Yuan, et al.
Publicado: (2021)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
por: Heini, Alexander D., et al.
Publicado: (2022)

Relapsed mantle cell lymphoma presenting with lactic acidosis and hypoglycemia: A case report
por: Carson, Lucy, et al.
Publicado: (2023)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects
por: Zumla, Alimuddin, et al.
Publicado: (2016)

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
por: Qualls, David, et al.
Publicado: (2022)

Interest of FDG-PET in the Management of Mantle Cell Lymphoma
por: Bailly, Clément, et al.
Publicado: (2019)

Novel and emerging therapies for B cell lymphoma
por: Ayyappan, Sabarish, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aa60ssco0vitj65q331utnk05q